Session

IBD (Posters)

LOSS OF RESPONSE AND DOSE ESCALATION OF INFLIXIMAB AND ADALIMUMAB IN ULCERATIVE COLITIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
LOSS OF RESPONSE AND DOSE ESCALATION OF INFLIXIMAB AND ADALIMUMAB IN ULCERATIVE COLITIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

SCREENING FOR SARCOPENIA IN CROHN'S DISEASE, SHOULD IT BE A MUST?
SCREENING FOR SARCOPENIA IN CROHN'S DISEASE, SHOULD IT BE A MUST?

MYCOBACTERIUM AVIUM PARATUBERCULOSIS INCIDENCE IN PATIENTS WITH CROHN’S DISEASE AND CONTROLS: A SINGLE CENTRE STUDY
MYCOBACTERIUM AVIUM PARATUBERCULOSIS INCIDENCE IN PATIENTS WITH CROHN’S DISEASE AND CONTROLS: A SINGLE CENTRE STUDY

IMPACT OF BIOLOGIC ERA ON COLECTOMY RATE OF ULCERATIVE COLITIS; ASSESSMENT OF 22 YEAR IN A TERTIARY REFERRAL CENTER COHORT FROM A DEVELOPING COUNTRY
IMPACT OF BIOLOGIC ERA ON COLECTOMY RATE OF ULCERATIVE COLITIS; ASSESSMENT OF 22 YEAR IN A TERTIARY REFERRAL CENTER COHORT FROM A DEVELOPING COUNTRY

CUTANEOUS MANIFESTATIONS IN BIOLOGICAL-TREATED PEDIATRIC INFLAMMATORY BOWEL DISEASE: A 10 YEARS’ EXPERIENCE FROM A TERTIARY CENTER
CUTANEOUS MANIFESTATIONS IN BIOLOGICAL-TREATED PEDIATRIC INFLAMMATORY BOWEL DISEASE: A 10 YEARS’ EXPERIENCE FROM A TERTIARY CENTER

RESTORATION OF MICROBIOME COMPOSITION AND INCREASED BUTYRATE PRODUCTION ARE ASSOCIATED WITH RESPONSE TO SYSTEMIC CORTICOSTEROIDS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS
RESTORATION OF MICROBIOME COMPOSITION AND INCREASED BUTYRATE PRODUCTION ARE ASSOCIATED WITH RESPONSE TO SYSTEMIC CORTICOSTEROIDS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS

SARS-COV-2 INFECTION DOES NOT WORSEN THE CLINICAL COURSE OF INFLAMMATORY BOWEL DISEASE: A 1-YEAR PROSPECTIVE CASE-CONTROL STUDY
SARS-COV-2 INFECTION DOES NOT WORSEN THE CLINICAL COURSE OF INFLAMMATORY BOWEL DISEASE: A 1-YEAR PROSPECTIVE CASE-CONTROL STUDY

NAFLD AND LIVER FIBROSIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A CASE-CONTROL STUDY
NAFLD AND LIVER FIBROSIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A CASE-CONTROL STUDY

PARAMETERS AFFECTING FISTULA TREATMENT RESPONSE IN PERIANAL FISTULIZING CROHN’S DISEASE UNDER BIOLOGICAL THERAPY: A MACHINE LEARNING MODEL STUDY
PARAMETERS AFFECTING FISTULA TREATMENT RESPONSE IN PERIANAL FISTULIZING CROHN’S DISEASE UNDER BIOLOGICAL THERAPY: A MACHINE LEARNING MODEL STUDY

EFFECTIVENESS OF SARS-COV2 BOOSTER VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): PRELIMINARY REPORT FROM A SINGLE REFERRAL CENTER IN SOUTHERN ITALY
EFFECTIVENESS OF SARS-COV2 BOOSTER VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): PRELIMINARY REPORT FROM A SINGLE REFERRAL CENTER IN SOUTHERN ITALY

PREDICTIVE FACTORS OF MALNUTRITION IN PATIENTS WITH INFLAMMATORY BOWELDISEASES
PREDICTIVE FACTORS OF MALNUTRITION IN PATIENTS WITH INFLAMMATORY BOWELDISEASES

INFLAMMATORY BOWEL DISEASE WITH CONCOMITANT ENDOMETRIOSIS: FREQUENCY AND CHARACTERIZATION IN A CASE-CONTROL PROSPECTIVE STUDY
INFLAMMATORY BOWEL DISEASE WITH CONCOMITANT ENDOMETRIOSIS: FREQUENCY AND CHARACTERIZATION IN A CASE-CONTROL PROSPECTIVE STUDY

PARTICULATE MATTER FROM NATURAL PRECURSOR INCREASES SUSCEPTIBILITY TO INFLAMMATORY BOWEL DISEASE
PARTICULATE MATTER FROM NATURAL PRECURSOR INCREASES SUSCEPTIBILITY TO INFLAMMATORY BOWEL DISEASE

THE USE OF NUTRITION AS A THERAPEUTIC STRATEGY IN CHILDREN AND ADOLESCENTS WITH CROHN’S DISEASE IN BELGIUM
THE USE OF NUTRITION AS A THERAPEUTIC STRATEGY IN CHILDREN AND ADOLESCENTS WITH CROHN’S DISEASE IN BELGIUM

NEED FOR VEDOLIZUMAB INTENSIFICATION IN REAL LIFE CLINICAL PRACTICE
NEED FOR VEDOLIZUMAB INTENSIFICATION IN REAL LIFE CLINICAL PRACTICE

A PROSPECTIVE INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF HYPOXIA ON HEALTHY VOLUNTEERS AND PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ALTITUDE IBD STUDY
A PROSPECTIVE INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF HYPOXIA ON HEALTHY VOLUNTEERS AND PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ALTITUDE IBD STUDY

EFFECTS OF REPEAT INFLIXIMAB TO STEADY STATE ON BLOOD PROINFLAMMATORY BIOMARKERS TNF-ALPHA, IL-6, IFN-GAMMA AND NITRITE/NITRATE IN CROHN’S DISEASE
EFFECTS OF REPEAT INFLIXIMAB TO STEADY STATE ON BLOOD PROINFLAMMATORY BIOMARKERS TNF-ALPHA, IL-6, IFN-GAMMA AND NITRITE/NITRATE IN CROHN’S DISEASE

PROACTIVE INFLIXIMAB IS MORE EFFECTIVE THAN VEDOLIZUMAB IN INDUCING FECAL CALPROTECTIN REMISSION IN INFLAMMATORY BOWEL DISEASE
PROACTIVE INFLIXIMAB IS MORE EFFECTIVE THAN VEDOLIZUMAB IN INDUCING FECAL CALPROTECTIN REMISSION IN INFLAMMATORY BOWEL DISEASE

GENOMIC DIVERSITY OF FAECALIBACTERIUM PRAUSNITZII STRAINS FROM MICROBIOTA OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES AND HEALTHY VOLUNTEERS
GENOMIC DIVERSITY OF FAECALIBACTERIUM PRAUSNITZII STRAINS FROM MICROBIOTA OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES AND HEALTHY VOLUNTEERS

ADAPTATION OF QUESTIONNAIRES USED IN THE TRANS-IBD RANDOMISED CLINICAL TRIAL
ADAPTATION OF QUESTIONNAIRES USED IN THE TRANS-IBD RANDOMISED CLINICAL TRIAL

Item 1 - 20 / 612
1
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31